These results also point the CD200:CD200R1 expression profile might be useful to follow up rectal cancer progression by virtue of their connection to recurrence risk, metastasis, and survival depending on the treatment modality, whereas rectal cancer patients appear to be targets for adjuvant therapies directed at interrupting CD200:CD200R1 immunoregulatory axis. The gene discussed is CD200; the disease is rectal cancer.